FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 486 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Cervical screening in Wales extended to every 5 years: Why the... January 7, 2022 FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... September 8, 2025 Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... November 29, 2021 Load more HOT NEWS Five Questions With…Linda. Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... How We’re Working to Build a Cancer Survivorship Community: Survivors’ Perspectives Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She...
